Jeff Yass’s Adial Pharmaceuticals ADIL Stock Holding History

Jeff Yass’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-52	Closed	-$88K	–	12884
2021 Q4	$88K	Sell	52 -32	-38%	-$63K	﹤0.01%	12220
2021 Q3	$224K	Buy	+84	New	+$176K	﹤0.01%	11229

Other funds holding ADIL

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MCM

Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RWM

Raffa Wealth Management Washington, District of Columbia $793M AUM 13.11% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jeff Yass's ADIL Position: Q1 2026 in Review

Jeff Yass sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 483 shares — an estimated $2.66K sold.

Jeff Yass first reported a position in ADIL in Q1 2020 and held it in 9 quarters. The position peaked at $133K in Q2 2022. 15 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

Jeff Yass reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jeff Yass sold 483 Adial Pharmaceuticals shares in Q1 2026, an estimated $2.66K.
Jeff Yass first reported a position in Adial Pharmaceuticals in Q1 2020 and held it in 9 quarters.
Jeff Yass's Adial Pharmaceuticals position peaked at $133K in Q2 2022.
15 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.